Clinical Trial Update: A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL [NA]

View source ↗

Summary

A single-arm clinical trial is evaluating acalabrutinib in combination with obinutuzumab in Chinese patients with previously untreated chronic lymphocytic leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Calquence (acalabrutinib) (acalabrutinib)
• Gazyva (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Chronic Lymphocytic Leukemia | NA | Status: RECRUITING